Chloroquine as Antiviral Treatment in Coronavirus Infection 2020
- Registration Number
- NCT04331600
- Lead Sponsor
- Wroclaw Medical University
- Brief Summary
The aim of the study is to evaluate whether the therapy with chloroquine phosphate (CQ, in combination with telemedical approach) in addition to standard care is effective and safe in reducing composite endpoint of COVID-19-related hospitalization or all cause death, in ambulatory patients with SARS-SoV-2 infection at particular risk of serious complications due to advanced age and/or comorbid conditions (in comparison with subjects not treated with CQ but receiving standard care and supervised telemedically).
- Detailed Description
Until now there are no evidence-based, good-quality data from sufficiently powered clinical trials supporting the use of any antiviral medicines or immunomodulatory therapies in the management or prophylaxis of COVID-19; however there are currently being initiated studies in Europe and U.S., and a few registered studies are ongoing in China. Currently two groups of medicines are hypothesized to be effective therapeutic options in COVID-19: (1) classical antiviral drugs interfering with pathogen dissemination / replication, and (2) compounds inhibiting host inflammatory reactions, especially (and potentially selectively) in respiratory tract / system (cytokine inhibitors and specific antibodies). Special hopes are placed in quinoline derivatives such as chloroquine (CQ), based on some unpublished data from China and a few experiments in vitro. CQ is an old antimalarial drug that has been used for more than 50 years in the therapy and prevention of this parasitosis. Anti-inflammatory features of quinolone derivatives such as CQ or hydroxychloroquine have also been used in rheumatology (for the therapy of lupus erythematosus or rheumatoid arthritis) due to the inhibition of the production of proinflammatory cytokines. The effectiveness (and safety) of CQ in COVID-19 has not been investigated in sufficiently powered RCTs until now.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 16
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description CONTROL GROUP Telemedicine Standard of care + telemedical approach. CHLOROQUINE Telemedicine Standard of care + chloroquine phosphate + telemedical approach. CHLOROQUINE Chloroquine phosphate Standard of care + chloroquine phosphate + telemedical approach.
- Primary Outcome Measures
Name Time Method COVID-19-related hospitalization or all-cause death 15 days Composite endpoint of COVID-19-related hospitalization or all-cause death
- Secondary Outcome Measures
Name Time Method Development of pneumonia 42 days Based on X-ray, microbiology and laboratory results
Development of coronavirus infection-related complications 42 days Acute respiratory distress syndrome, bacterial infection, shock, sepsis, etc
Decrease in COVID-19 symptoms 15 days and 42 days Decrease in self-reported symptoms of novel coronavirus infection. Non-dichotomous symptoms (e.g. syncope is dichotomous - yes or no) such as dyspnoea will be self-evaluated by patients using the 0-3 scale with the severity increasing with the punctation (0-no symptoms, 1-mild symptoms, 2-moderate symptoms, 3-severe symptoms).
Trial Locations
- Locations (2)
Uniwersytecki Szpital Kliniczny
🇵🇱Wrocław, Ul. Borowska 213, Poland
Wielospecjalistyczny Szpital Miejski
🇵🇱Poznań, Ul. Szwajcarska 3, Poland